My Ultimate Sign-in System Made Me Invincible

Chapter 465  Hands Are Tied (3)

The emergency session in Moscow had been convened with unusual speed, pulling ministers and military officials from their evening obligations with minimal explanation beyond “immediate national security concern.”

The room was secure, windowless, and contained people who understood that what they discussed here would not leave these walls unless explicitly authorized.

The Defense Minister spoke first, his tablet displaying the Medical Nanites announcement in Russian translation. “This changes the strategic calculus entirely. We’ve been monitoring Nova Technologies since the Lucid device appeared. Our intelligence services have found nothing. No supply chains we can identify. No manufacturing facilities we can locate. No personnel we can track. And now they announce medical technology that makes our entire defense medical corps obsolete and claim to have a facility in space that we never detected.”

The Foreign Minister leaned forward. “The Americans received advance warning. Five hours. Enough to convene their own emergency meetings before the public announcement. That tells us something about the relationship between Nova Technologies and Washington.”

“It tells us they have a back channel,” someone else added. “Through Whitlock, most likely. But five hours isn’t cooperation. It’s a courtesy. The Americans are just as blind as we are.”

The silence that followed was heavy with implications no one wanted to articulate directly.

The head of the state technology development corporation spoke carefully. “Our research institutes have been attempting to reverse-engineer the Lucid device’s capabilities since Month One. Progress has been… limited. The wireless connectivity alone operates on principles we don’t understand. Adding medical nanites to the equation—nanites that can regrow organs and reverse neurological damage—means we’re not looking at incremental technological advantage. We’re looking at a civilization-level gap.”

“Can we acquire the technology?” The question came from someone whose title was deliberately vague but whose presence indicated SVR involvement.

“Through what mechanism?” the Defense Minister asked. “Corporate espionage assumes there’s something to steal. We don’t even know where their R&D happens. The off-world facility suggests space-based operations, but our satellite tracking hasn’t identified any launches that could support that kind of infrastructure. Either they’re launching from locations we’re not monitoring, or they have capabilities we can’t detect.”

The intelligence official’s expression suggested he’d already explored multiple avenues and found them all blocked. “We’ve attempted to recruit their personnel. There are no personnel to recruit that we can identify. We’ve attempted to trace their financial flows. The transactions are routed through systems we can’t penetrate. We’ve attempted to identify their facilities. They don’t appear to exist in any conventional sense.”

“What about the clinical trials?” the Foreign Minister suggested. “They’re inviting international observers. We could send representatives. Get access to the facility. Understand the technology firsthand.”

“As observers,” the Defense Minister said flatly. “With no ability to acquire samples, no access to underlying systems, no transfer of intellectual property. We’d be watching from the outside while they demonstrate capabilities we can’t replicate.”

“That’s still more than we have now.”

“Is it? Or is it just making our technological inferiority more visible?”

The room absorbed that question without answering it directly.

The economic advisor spoke for the first time. “The larger strategic concern is what this does to our geopolitical position. We’ve maintained influence through energy exports, military capability, and the ability to project power in our sphere. Medical nanites undermine all three. Energy becomes less valuable when technology advances beyond our capacity to match. Military capability becomes irrelevant when our adversaries have medical technology that makes casualty rates negotiable. And sphere influence collapses when we can’t provide our allies with access to life-saving technology they can get elsewhere.”

“You’re suggesting we lose strategic leverage across multiple domains simultaneously.”

“I’m suggesting that if this technology works as described, the global order restructures around whoever controls access to it. And we don’t control access. We don’t even have a pathway to controlling access.”

Another long silence.

The senior official who’d been listening without speaking finally leaned forward. “Our position is clear. We participate in the clinical trial observation. We maintain diplomatic relations with whatever entities are willing to serve as intermediaries. We continue research into comparable technologies even if success seems unlikely. And we do not—under any circumstances—take actions that could be interpreted as hostile toward an organization whose capabilities we don’t understand and can’t counter.”

He looked around the room. “We’ve faced technological disadvantages before. We’ve always found ways to adapt, to leverage asymmetric advantages, to remain relevant despite gaps in capability. This situation is no different. It’s simply more pronounced.”

“And if the gap becomes too large to bridge?”

“Then we ensure we’re positioned to benefit from the technology’s existence rather than being destroyed by our opposition to it.”

The meeting concluded without formal decisions, only strategic direction. Russia would observe, adapt, and avoid confrontation with forces it couldn’t control.

***

# Middle East

The private council chamber in one of the Gulf capitals contained individuals whose wealth was measured in billions and whose influence extended across multiple nations. They met infrequently and only for matters of genuine strategic importance.

Medical nanites qualified.

The eldest among them, a man whose family had controlled significant resources for three generations, spoke with the kind of calm that came from having navigated multiple oil crises and regional conflicts. “We’ve built our position on three foundations: energy wealth, strategic location, and the ability to acquire whatever technology money can buy. Nova Technologies challenges the third foundation directly.”

“They’re not selling access,” someone pointed out. “The Lucid device is lottery-based. Money doesn’t guarantee entry.”

“Which is precisely the problem. We’re accustomed to markets where capital creates access. This is a market where capital is irrelevant to the entry mechanism. Our wealth gives us no advantage in acquiring the foundational technology required for the medical nanites.”

A younger member, educated in London and representing newer money, pulled up analysis on his tablet. “The subscription model is actually accessible. Even the Sovereign tier is only $60,000 annually. That’s nothing. The barrier isn’t cost once you’re in the ecosystem. The barrier is getting into the ecosystem at all.”

“So we need Lucid devices.”

“We need Lucid devices for ourselves, our families, our key personnel. But the pre-order system makes that nearly impossible. Ten thousand units globally next month. Millions trying to acquire them. Even with the best internet infrastructure money can buy, the odds are terrible.”

“What about alternative acquisition?” The question was posed carefully, with the kind of diplomatic phrasing that acknowledged certain methods without endorsing them explicitly.

“We’ve explored secondary markets. Current holders won’t sell because the ongoing income potential exceeds any one-time payment we can offer. We’ve explored potential partnerships with Nova Technologies through intermediaries. They’ve been politely unresponsive. We’ve explored whether governments might secure access for us. The Americans can’t even secure access for themselves.”

The eldest member nodded slowly. “Then we’re in the same position as everyone else. Hoping for lottery success while planning for the implications of failure.”

“There’s another consideration,” the economic strategist added. “If medical nanites eliminate chronic disease and extend healthy lifespan significantly, what happens to our demographic advantage? We have young populations. That’s been a strategic asset. But if age becomes less relevant because people remain healthy and productive indefinitely, we lose that advantage relative to aging Western nations who can simply… stop aging.”

“You’re suggesting this technology helps our competitors more than it helps us.”

“I’m suggesting it neutralizes one of our few asymmetric advantages while we have no guaranteed access to the technology creating that neutralization.”

The room considered this in silence.

The eldest member spoke again. “Our approach is threefold. First, we participate in the clinical trial observation. We send our best medical professionals to witness the technology firsthand. Second, we attempt to enter the Lucid ecosystem through every legitimate channel available. Third, we begin planning for a future where this technology exists and is widely distributed, because whether we like it or not, that future is coming.”

“And if we can’t acquire access?”

“Then we ensure our next generation is positioned to acquire it. This is a long game now.”

***

# Singapore

The ministerial briefing room was smaller than those in Moscow or the Gulf, but the efficiency of the discussion was characteristically precise.

The Minister for Trade and Industry had already reviewed the announcements three times before the meeting began. Now he addressed the small group of senior officials with characteristic directness. “Nova Technologies represents both an opportunity and a threat. The opportunity is clear: if we can position ourselves as a favorable jurisdiction for their operations, we gain economic and strategic advantages. The threat is equally clear: if we can’t, we become irrelevant in sectors we’ve spent decades developing.”

The Health Minister pulled up healthcare expenditure data. “Our medical technology sector is worth approximately $15 billion annually. Medical tourism contributes another $3 billion. Both become threatened if nanites function as described. But they also represent an opportunity if we can become a regional hub for nanite deployment.”

“That assumes Nova Technologies wants regional hubs,” someone pointed out.

“It assumes we make ourselves useful enough that they want us involved. We have regulatory efficiency. We have technical infrastructure. We have a reputation for reasonable governance. Those are assets we can leverage.”

The Economic Development Board representative leaned forward. “The clinical trials are off-world, but the technology will eventually need terrestrial distribution infrastructure. We should position ourselves as the optimal location for Asian-Pacific operations. Offer favorable regulatory treatment. Streamline approval processes. Make it easier for them to operate here than anywhere else in the region.”

“The Americans will do the same.”

“The Americans have Congressional gridlock and fifty different state regulatory frameworks. We can move faster and with more coherence.”

The Minister for Trade and Industry nodded. “Draft a proposal. Favorable jurisdiction status, streamlined medical device approval, whatever incentives we can offer within our existing frameworks. We’re not trying to control Nova Technologies. We’re trying to make ourselves the path of least resistance for their expansion.”

“And if they’re not interested?”

“Then we’ve lost nothing but preparation time. But if they are interested, we’ve positioned ourselves to benefit from the largest medical technology deployment in human history. That’s worth the effort.”

The meeting concluded with action items and timelines. Singapore would compete not through confrontation or demands, but through making itself indispensable.

Different nations, different strategies. But the same recognition: the world had changed, and adaptation was the only viable response.

Within seventy-two hours of the Medical Nanites announcement, nearly every major government on Earth had arrived at the same conclusion through different pathways: they would send observers to the clinical trials, avoid any action that could be interpreted as hostile toward Nova Technologies, and begin positioning themselves to benefit from rather than oppose a technology they couldn’t control, replicate, or regulate.

China maintained its public ban on Lucid devices while quietly exploring diplomatic channels. Japan emphasized scientific collaboration and offered research partnerships. India focused on becoming a favorable jurisdiction for future deployment. Brazil, Canada, Australia, and dozens of smaller nations submitted observer requests with carefully worded statements that acknowledged the technology’s significance without conceding regulatory authority they no longer effectively possessed.

The pattern was universal: adapt, observe, and hope that cooperation would eventually provide leverage that confrontation demonstrably could not. No nation chose opposition, because every strategic analysis—whether driven by military concern, economic interest, or institutional pride—concluded that fighting an organization with off-world infrastructure and physics-defying technology while offering nothing their citizens desperately wanted was a path to irrelevance at best and catastrophic failure at worst.